MA56130A - Procédés de culture cellulaire et compositions pour la production d'anticorps - Google Patents

Procédés de culture cellulaire et compositions pour la production d'anticorps

Info

Publication number
MA56130A
MA56130A MA056130A MA56130A MA56130A MA 56130 A MA56130 A MA 56130A MA 056130 A MA056130 A MA 056130A MA 56130 A MA56130 A MA 56130A MA 56130 A MA56130 A MA 56130A
Authority
MA
Morocco
Prior art keywords
antibodies
compositions
production
cell culture
culture methods
Prior art date
Application number
MA056130A
Other languages
English (en)
Inventor
Yogender Kumar Gowtham
Sokha Susan Lay
Edmund G Scarfo
Nandita Vishwanathan
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA56130A publication Critical patent/MA56130A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
MA056130A 2019-06-10 2020-06-10 Procédés de culture cellulaire et compositions pour la production d'anticorps MA56130A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859563P 2019-06-10 2019-06-10
US201962859596P 2019-06-10 2019-06-10

Publications (1)

Publication Number Publication Date
MA56130A true MA56130A (fr) 2022-04-13

Family

ID=73780813

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056130A MA56130A (fr) 2019-06-10 2020-06-10 Procédés de culture cellulaire et compositions pour la production d'anticorps

Country Status (14)

Country Link
US (1) US20220267448A1 (fr)
EP (1) EP3980068A4 (fr)
JP (1) JP2022536658A (fr)
KR (1) KR20220019725A (fr)
CN (1) CN114206383A (fr)
AU (1) AU2020291920A1 (fr)
BR (1) BR112021024852A2 (fr)
CA (1) CA3143246A1 (fr)
IL (1) IL288819A (fr)
MA (1) MA56130A (fr)
MX (1) MX2021015301A (fr)
PL (1) PL439808A1 (fr)
TW (1) TW202112819A (fr)
WO (1) WO2020252082A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023021532A1 (fr) * 2021-08-20 2023-02-23 Dr. Reddy’S Laboratories Limited Procédé de production d'une composition pharmaceutique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP2243827B2 (fr) * 1996-08-30 2017-11-22 Life Technologies Corporation Milieu de culture de cellules de mammiferes exempt de serum
CA2629147A1 (fr) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Immunoglobuline humanisee reactive avec l'integrine .alpha.4.beta.7
US8911964B2 (en) * 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CA2682170A1 (fr) * 2007-03-30 2008-10-09 Medimmune, Llc Anticorps presentant des profils de desamidation reduits
CN104024423B (zh) * 2011-04-29 2017-03-15 拜康研究有限公司 用于降低抗体异质性的方法和产生其抗体的方法
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
HU231463B1 (hu) * 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Módszer rekombináns proteinek galaktóz tartalmának növelésére
JP6794448B2 (ja) * 2015-12-04 2020-12-02 ノバルティス アーゲー 抗体サイトカイングラフト組成物および免疫調節のための使用方法

Also Published As

Publication number Publication date
JP2022536658A (ja) 2022-08-18
CA3143246A1 (fr) 2020-12-17
AU2020291920A1 (en) 2022-02-03
EP3980068A1 (fr) 2022-04-13
EP3980068A4 (fr) 2023-05-31
US20220267448A1 (en) 2022-08-25
TW202112819A (zh) 2021-04-01
IL288819A (en) 2022-02-01
WO2020252082A1 (fr) 2020-12-17
CN114206383A (zh) 2022-03-18
BR112021024852A2 (pt) 2022-02-15
PL439808A1 (pl) 2022-12-05
KR20220019725A (ko) 2022-02-17
MX2021015301A (es) 2022-02-03

Similar Documents

Publication Publication Date Title
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
MA52186A (fr) Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA51993A (fr) Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MA32126B1 (fr) Anticorps et immunoconjugués anti-cd79b et leurs procédés d'utilisation
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
EP3917564A4 (fr) Anticorps anti-claudine 18 et leurs méthodes d'utilisation
MA49045A (fr) Compositions et procédés destinés à la distribution régulée d'acide
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA32535B1 (fr) Compositions et procédés pour des anticorps ciblant une protéine du complément c5
MA47425A (fr) Composition pharmaceutique à faible ph comprenant des constructions d'anticorps d'engagement avec les lymphocytes t
MA32391B1 (fr) Activateurs de la glucokinase
MA53811A (fr) Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation
MA33210B1 (fr) Nouveaux anticorps anti-a5b1 et leurs utilisations
MA47775A (fr) Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
PH12018500747B1 (en) Fly ash, cement composition, and method of preparing fly ash
EP3849568A4 (fr) Compositions d'organoïdes pour la production de cellules souches hématopoïétiques et leurs dérivés
MA56130A (fr) Procédés de culture cellulaire et compositions pour la production d'anticorps
MA53391A (fr) Compositions pour l'agriculture et procédés associés
MA55284A (fr) Procédés de production de compositions d'anticorps anti-tnf
MA30265B1 (fr) Procedes et compositions destines a cibler relt
MA53557A (fr) Procédés de culture cellulaire continue
MA51997A (fr) Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur
FR3045035B1 (fr) Materiau de construction ductile